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Background: There is legitimate concern that minority drug-resistant mutants may be selected during the initial
HIV-1 RNA decay phase following antiretroviral therapy initiation, thus undermining efficacy of treatment. The goal
of this study was to characterize viral resistance emergence and address viral population evolution during the first
phase of viral decay after treatment containing initiation.
Findings: 454 sequencing was used to characterize viral genetic diversity and polymorphism composition of the
HIV-1 integrase gene during the first two weeks following initiation of raltegravir-containing HAART in four
ART-experienced subjects. No low-prevalence Raltegravir (RAL) drug resistance mutations (DRM) were found at
baseline. All patients undergoing treatment received a fully active ART according to GSS values (GSS ≥ 3.5). No
emergence of DRM after treatment initiation was detected. Longitudinal analysis showed no evidence of any other
polymorphic mutation emergence or variation in viral diversity indexes.
Conclusions: This suggests that fully active salvage antiretroviral therapy including raltegravir achieves a complete
blockade of HIV-1 replication in plasma. It is unlikely that raltegravir-resistant HIV-1 may be selected in plasma
during the early HIV-1 RNA decay after treatment initiation if the administered therapy is active enough.
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There is legitimate concern that minority drug-resistant
mutants may be selected during the initial HIV-1 RNA
decay phase following antiretroviral therapy initiation,
when decreasing but still detectable HIV-1 RNA levels
transiently coexist with suboptimal drug levels. Studies
using allele-specific PCR suggested that drug-resistant
HIV-1 might be selected and replicate in the first weeks
of suppressive antiretroviral therapy (ART) [1,2]. If they
were confirmed, such observations would support using
intensified ART regimens to accelerate viremia suppres-
sion and curtail drug resistance evolution, but not only in* Correspondence: mnoguera@irsicaixa.es
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article, unless otherwise stated.treatment-naïve subjects initiating first-line ART. Achiev-
ing fast blockade of HIV replication would even be more
important in subjects with drug-resistant HIV-1 initiating
salvage ART, given that they are more vulnerable to drug
resistance evolution and are closer to exhausting their
treatment options.
In the past, however, first-line treatment with 4, 5, or
more antiretrovirals did not produce better virological
outcomes than standard 3-drug ART [3]. Indeed, evolu-
tionary studies in macaque models [4] suggested that
viral replication was completely shut down by therapy
and that development of antiretroviral drug resistance
during the initial viremia decay was unlikely to occur,
provided that treatments were active enough and resist-
ant variants did not pre-exist. If HIV replication could
be shut down with standard ART, addition of furtherCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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protection against drug resistance.
Mathematical models of HIV resistance kinetics pre-
dict faster selection of resistant viruses with more potent
regimens. On the other hand, previous studies correlated
higher resistance selection with longer time to achieving
undetectable HIV-1 RNA levels [1,2]. raltegravir (RAL)
achieves fast viremia suppression when combined with
an optimized backbone treatment (OBT) [5], but has a
low-genetic barrier and HIV-1 variants with single ralte-
gravir drug resistance mutations could pre-exist at low
levels [6,7].
We thus sought to explore in a proof-of-concept study
whether raltegravir-resistant mutants were selected dur-
ing the initial HIV-1 RNA decay following initiation of
raltegravir-containing ART in 4 treatment-experienced
subjects with HIV-1 resistance to at least 2 antiretroviral
drug classes using ultrasensitive, quantitative 454 sequen-
cing. We also sought to characterize the diversity and viral
population shifts in HIV-1 integrase during this initial
HIV-RNA decay phase.Study design
The study included 4 ART-experienced HIV-1-infected
subjects who initiated salvage ART including raltegravir
(RAL) with more than 3 active drugs (Table 1). All sub-
jects provided signed informed consent to participate into
the study. The Ethics Committee of the “Germans Trias i
Pujol” Hospital, approved the study on 21 December




Date of diagnostic 13/05/96 0
Transmission type Heterosexual
Previous ART lines 9
#drugs before RAL 13






ART ddI + 3TC + DRV/r + RAL TDF/FTC
GSS 4
Baseline CD4 (cells/mm3) 614
Intravenous Drug Use (IVDU); Genotypic Sensitivity Score (GSS, Stanford HIVdb), NR
Nucleoside-analogues Reverse Transcriptase Inhibitor; PI: Protease Inhibitor; Daruna
Emtricitabine (FTC); Tenofovir (TDF); Etravirine (ETV); Enfuvirtide (T-20); Maraviroc (Mperformed using 454 Genome Sequencer FLX (Life Se-
quencing/Roche) in consecutive plasma samples with
detectable viral loads on days 0 to 14 following RAL initi-
ation. 454 sequencing of integrase was performed using
a four-amplicon design for robustness (see Additional
file 1). A homology filter was applied to rule out pNL43
contamination. AVA v2.8 software was used to obtain mu-
tation prevalence and unique consensus sequences, which
were further processed. Short consensus sequences (less
than 90% of the expected length) were filtered out. Ami-
noacid variant calling was realized using in-house perl
code on pairwise alignments over HXB2R reference se-
quence, discarding those sequences with in-frame STOP
codons. In order to discard strand-dependent sequencing
errors, only variants which were present both in the for-
ward and reverse strand and presented a forward/reverse
prevalence frequency ratio within 1 log were accepted.
GSS scores were calculated using Stanford HIVdb
guidelines. MAFFT (v6.815b) software [8] was then used
to perform multiple alignment on consensus sequences.
Shannon entropy was calculated for each amplicon
using the alignment obtained and the prevalence infor-
mation kept for each position. Mean pairwise distances
(both intra amplicon and relative to an HXB2 reference)
were calculated using a Kimura-80 model and sequence
prevalence information with R/ape package [9].Results
The genotypic susceptibility score (GSS) of the salvage












+ DRV/r + RAL TDF/FTC + DRV/r + RAL + T-20 DRV/r + RAL +MVC
3.5 3.5 3.5
300 332 399
TI: Nucleoside-analogues Reverse Transcriptase Inhibitor; NNRTI non-
vir (DRV); Didanosine (DDI); Lamivudine (3TC); Raltregravir (RAL); Ritonavir (RTV);
VC).
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considering 454 deep sequencing data obtained for inte-
grase and protease/retrotranscriptase, when available
(see Additional file 2: Table S1). At baseline, median
(interquartile range) for HIV-1 ARN and CD4+ T cell
counts were, 116.500 (57.750; 215.000) copies/mL and
399 (300;614) cells/mm3. Viral load decline at day 7,
when available, was more than 1log copies/mL.
The median number of sequences obtained from 454
sequencing per amplicon was 3404 (IQR: 1497–5304).Viral Load(copies/mL) 230.000 136.000 24.000 3.600 
Days after ART initiation 0 3 5 7 
170.000 280.000 31.000 6.000 
0 3 5 7 
Viral Load(copies/mL) 
Days after ART initiation
Figure 1 Longitudinal evolution of integrase polymorphisms relative
polymorphisms are in the vertical axis. The horizontal axis shows the differe
decay. The frequency of each polymorphism is represented using a color s
indicates non detection of polymorphisms. A remarkable stability in polym
(2013) integrase resistant mutations were found.Initiation of treatment with raltegravir was associated
with a rapid decline in HIV-1 RNA levels but no changes
in integrase diversity or shifts relative to an HXB2R exter-
nal reference (see Additional file 3: Figures S1, S2 and
Additional file 2: Table S2). The frequency of major inte-
grase polymorphisms remained stable during the viral
load decay phase (Figure 1). In addition, longitudinal 454
sequencing of integrase gene did not result in the emer-
gence of resistant mutations or any of the detected
polymorphisms and, so, sensitivity to RAL remained56.000 19.000 4.400 5.100 
0 3 5 7 
900 
10 
63.000 17.000 15.000 5.700 
0 3 5 10 
2.400 
14 
to Consensus B. Each plot corresponds to one subject. Integrase
nt longitudinal timepoints assessed during the initial HIV-1 RNA load
cale, from 100% (dark red) to a 1.0% threshold (light blue). White
orphism type and frequency is observed. Of note, none of the IAS-list
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minor viral populations carrying minor polymorphisms
were selected.
Discussion
We observed stability of HIV-1 integrase diversity and
heterogeneity within the first phase of HIV-1 RNA decay.
The type and frequency of polymorphisms in sequential
samples during early HIV-1 RNA decay suggests that
salvage antiretroviral therapy including raltegravir is able
to achieve an effective blockade of HIV-1 replication in
plasma, even in heavily treatment-experienced individuals,
in a context where a potent antiretroviral regimen, defined
by a GSS ≥ 3, can be constructed. Of note, the rapid de-
cline on HIV-1 RNA levels may also affect the capability
of detecting minor polymorphisms using 454. When the
number of obtained sequences is higher than the number
of expected initial viral templates, re-sequencing of the
same minor variants may lead to an artifactual appearance
of low prevalence polymorphisms. Interestingly, minority
polymorphisms were more frequent and fluctuated at later
time points, at very low levels. Thus, obtained minor vari-
ant frequencies must be interpreted accounting for sam-
pling limitations. Conversely, sampling limitations are not
expected to significantly affect viral diversity due to the
much larger impact of highly prevalent variants over mi-
nority ones in these measures.
Importantly, the blockade in replication observed in
this study must be understood as a result of the global
antiretroviral treatment pressure against the whole viral
quasi-species. Indeed, additional 454 data on protease
and reverse transcriptase at baseline confirms the full
potency of the prescribed regimen, as GSS scores were
not modified by the few minor resistant variants add-
itionally detected. Our findings contrast with the rapid
emergence of raltegravir resistance when non- fully active
regimens (GSS < 3) are used [6,7]. Also, antiretroviral drug
resistance might evolve in other compartments or reser-
voirs with low drug penetration in the presence of residual
HIV-1 replication. It is also worth noting that the sample
size in this study is low (n = 4), thus reducing our ability
to observe emergence of resistance, and that GSS in our
study ranged from 3.5 to 4, so we cannot conclude
whether a GSS = 3 would achieve similar results.
In conclusion, raltegravir-resistant HIV-1 may not be
selected in plasma during the early HIV-1 RNA decay
after salvage treatment initiation, provided that subjects
are given a fully effective regimen that is able to shut
down plasma replication. Further studies are required to
assess whether similar findings might also be observed
with other drugs or regimens and to clarify what is the
minimum GSS (i.e. 3, 4 or higher) required to block
HIV-1 evolution during HIV-1 RNA decay following
ART initiation.Additional files
Additional file 1: Methods for UDS-454 DNA library preparation
and primer design.
Additional file 2: Table S1. Drug resistant mutations at baseline for all
patients obtained from 454 Data. NRTI: Nucleoside-analogues Reverse
Transcriptase Inhibitor; NNRTI non- Nucleoside-analogues Reverse
Transcriptase Inhibitor; PI: Protease Inhibitor; INSTI: integrase strand transfer
inhibitor. Table S2. The evolution of HIV integrase diversity during the initial
HIV-1 RNA decay. VL: Viral Load, GSS: HIVdb Genotypic Susceptibility Score,
NA: Not available. Mean pairwise distance calculated vs HXB2R. Shannon
Entropy Score calculated for haplotype set multiple alignments. Table S3.
Number of sequence readouts obtained for each Sample/timepoint and Amplicon
before and after applying the pNL4-3 contamination filter to raw sequence
data. Percent values are shown when ≥0.1%. Table S4. Polymorphisms
frequencies at baseline as obtained for each amplicon separately. (NC: Not
Covered; N/A: No sequence data available).
Additional file 3: Figure S1. Longitudinal evolution mean pairwise
distance versus an external reference (HXB2R). Each boxplot shows results
from HXB2 referenced pairwise distance for the four integrase amplicons.
R/ape package, with a Kimura-80 model was used to calculate pairwise
distances. Figure S2. Longitudinal evolution of summed Shannon
Entropy values. Each boxplot shows results from Shannon Entropy values
calculated and collapsed for the four integrase amplicons in a particular
sample/timepoint combination.
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